Eszopiclone 3 mg/1

Eszopiclone, the active ingredient in Eszopiclone 3 mg, is a non-benzodiazepine hypnotic (cyclopyrrolone) presented as a 3 mg/1 film-coated tablet for oral use. It is indicated for the treatment of insomnia in adults. GNH USA supplies Eszopiclone 3 mg as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Eszopiclone 3 mg is a Schedule IV controlled substance, classified under the therapeutic class of sedative-hypnotics for insomnia. It is available in the USA and is subject to regulatory guidelines ensuring its safety and efficacy.

Eszopiclone 3 mg is primarily used for the treatment of insomnia. It acts on the GABA receptor complex, enhancing the effects of the neurotransmitter GABA to promote sleep. The following are the key indications for Eszopiclone 3 mg:

- Insomnia: Improves sleep onset and maintenance in adults with chronic or transient insomnia.

Eszopiclone 3 mg may cause various side effects, ranging from common to serious. It is important to be aware of these potential effects when using the medication.

Common Side Effects: - Dizziness: May occur during the day after taking the medication. - Headache: A frequent side effect reported by users. - Nausea: Some patients may experience mild to moderate nausea. - Dry mouth: A common side effect that can be managed with hydration. - Unpleasant taste: Some users report a bitter or metallic taste after taking the medication. - Daytime drowsiness: May occur, especially if the medication is not taken immediately before bedtime. - Diarrhea: A less common but possible side effect. - Fatigue: Some patients may feel tired during the day.

Serious or Rare Side Effects: - Complex sleep behaviors: Includes activities such as sleep-driving, which can be dangerous. - Memory impairment: May occur, especially if the medication is taken with less than a full night of sleep remaining. - Hallucinations: Rare but possible, especially in elderly patients. - Depression: Some patients may experience worsening of depressive symptoms.

Eszopiclone 3 mg should be used with caution and under the supervision of a healthcare provider. The following precautions should be considered:

- Dosage adjustment: The total dose should not exceed 2 mg in elderly or debilitated patients. - Next-day impairment: Patients should be cautioned against driving or engaging in hazardous activities the day after use. - Alcohol and CNS depressants: Avoid concomitant use with alcohol or other CNS depressants to prevent additive effects. - Hepatic impairment: The total dose should not exceed 2 mg in patients with severe hepatic impairment. - CYP3A4 inhibitors: Caution should be exercised when coadministered with potent CYP3A4 inhibitors. - Store at room temperature: Keep in the original pack, protect from moisture.

Eszopiclone 3 mg may interact with other medications, potentially altering its effectiveness or increasing the risk of side effects. The following interactions should be considered:

Major Interactions (Avoid): - Alcohol: Concomitant use increases the risk of CNS depression and complex sleep behaviors. - Other CNS depressants: Includes benzodiazepines, opioids, and tricyclic antidepressants, which can enhance the sedative effects of eszopiclone. - Ketoconazole: A potent CYP3A4 inhibitor that can significantly increase eszopiclone exposure.

Moderate Interactions (Monitor Closely): - Olanzapine: May result in a pharmacodynamic interaction affecting psychomotor function. - Lorazepam: May decrease each other’s Cmax by 22%, requiring close monitoring. - Paroxetine: No pharmacokinetic interaction has been detected, but monitoring is still recommended.